Biotech RadarJobs updated

COMPANY

Escient Pharmaceuticals

HQ: San Diego, CA source · escientpharma.com ↗

Clinical Phase 2

Keywords: chronic urticaria atopic dermatitis asthma Pruritus Chronic Spontaneous Urticaria Cholestasis Kidney Failure Chronic Inducible Urticaria EP547 EP262

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

  1. Trial start 1: An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration source ↗
  2. Trial start 2: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis source ↗
  3. Trial start 2: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria source ↗
  4. Trial start 1: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria source ↗
  5. Trial start Phase 2: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis source ↗
  6. Trial start Phase 1: Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus source ↗

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06077773Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria2TerminatedSep 25, 2023Dec 18, 2024 (actual)
NCT06144424Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis2CompletedOct 25, 2023Jul 31, 2024 (actual)
NCT04510090Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic PruritusPhase 1CompletedSep 7, 2020Jul 8, 2021 (actual)
NCT05525520Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisPhase 2CompletedOct 6, 2022Jul 17, 2024 (actual)
NCT06645704An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration1CompletedOct 1, 2024Dec 10, 2024 (actual)
NCT06050928Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria1CompletedAug 30, 2023Oct 22, 2024 (actual)
Feedback